Pfizer (NYSE:PFE) Bolsa

PFIZER INC

Pfizer

Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.

Warren Buffett Shutterstock

Equities

AAPL

ARCC

GBDC

LAMR

Conoce las nueve acciones de alto dividendo gestionadas por NEAM, filial de Berkshire Hathaway, en la estrategia de inversión de Buffett.

Acciones de alto dividendo que Berkshire Hathaway mantiene a través de NEAM

S&P 500

Analyst Color

AMZN

BKNG

GOOGL

MSFT

NVDA

NWSA

TSLA

El S&amp;P 500 logra su segundo trimestre consecutivo con ganancias de dos dígitos gracias a un 78 % de empresas superando expectativas.

S&amp;P 500 supera previsiones: 78 % de empresas baten ganancias en el primer trimestre

Medical,Billing,Document,And,Dollar,Banknote,,Calculator,,Stathoscope.,Medical,Treatment

Health Care

Markets

AMGN

REGN

RHHBY

Trump anuncia una orden ejecutiva para reducir precios de medicamentos hasta un 80 %, aplicando la política de &#34;Nación Más Favorecida&#34;.

Trump firma orden ejecutiva histórica para reducir precios de medicamentos en EE. UU.

Pfizer Inc

Innovator U.S. Equity Power Buffer ETF - February

PFEIFFER VACUUM TECH ORD by Pfeiffer Vacuum Technology AG

Pfeiffer Vacuum Technology AG

The Delaware Supreme Court has overturned a lower court&#8217;s decision that allowed expert testimony supporting plaintiffs&#8217; claims in a high-profile case alleging that Zantac, or its generic ranitidine, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38946928/gsk-concealed-risk-associated-with-discontinued-heart-burn-drug-zantac-whistleblower-lawsuit-clai" rel="noreferrer noopener">can cause cancer</a>.
The justices concluded that the trial court applied an incorrect legal standard when it ruled that the reliability of expert opinions should be determined by a jury rather than by the judge.
Initially marketed by a forerunner of&nbsp;GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), Zantac, once a blockbuster heartburn drug, has been sold at different times by companies, including&nbsp;Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Boehringer Ingelheim, Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), and <a target="_blank" href="https://www.benzinga.com/general/biotech/23/06/32917283/sanofi-stock-is-trading-higher-today-heres-why" rel="noreferrer noopener">several generic drugmakers</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/politics/25/07/46258994/trumps-big-beautiful-bill-hands-5-billion-win-to-big-pharma-report" rel="noreferrer noopener">Trump&#8217;s &#8216;Big, Beautiful Bill&#8217; Hands $5 Billion Win To Big Pharma: Report</a>
The case centers on nearly 75,000 plaintiffs who claim their cancer diagnoses were caused by exposure to ranitidine, the active ingredient in Zantac, which may degrade into the probable human carcinogen NDMA.
Plaintiffs submitted expert reports linking the drug to ten types of cancer, but the defendants challenged the validity of those reports, questioning the scientific methods used.
The Superior Court <a target="_blank" href="https://courts.delaware.gov/Opinions/Download.aspx?id=382080" rel="noreferrer noopener">denied</a> motions to exclude the expert opinions, citing Delaware&#8217;s &#8220;liberal thrust&#8221; toward admitting expert testimony. It found that any methodological disputes were issues for the jury.
The court also allowed the experts to base their causation claims on studies involving NDMA, rather than requiring a direct link to Zantac itself.
However, the Supreme Court found this reasoning flawed. In its opinion, the court emphasized that Delaware&#8217;s rules on expert evidence align with federal standards, which burden the proponent to prove that testimony is based on sufficient and reliable scientific methods.
The court also faulted the trial judge for improperly framing the central question of general causation. Rather than asking whether Zantac specifically could cause cancer, the lower court allowed experts to rely on data involving NDMA without demonstrating that Zantac exposure levels were comparable to those in the referenced studies.
The Supreme Court ruled that this failed to establish a scientifically valid connection between the product and the alleged harm.
In June, a federal judge ruled that key claims brought by plaintiffs against Patheon Manufacturing Services in the Zantac litigation may move forward, while one claim related to <a href="https://www.benzinga.com/general/biotech/22/12/29989120/relief-to-pfizer-sanofi-as-us-dismisses-several-lawsuits-associated-with-zantac" target="_blank" rel="noreferrer noopener">misrepresentation was dismissed</a>.
In its motion to dismiss, Patheon argued that the plaintiffs&#8217; claims failed on multiple fronts. The company said the plaintiffs did not identify a specific manufacturing defect, asserted that the design defect claim was preempted by federal law, and claimed that negligence was not pled with adequate specificity.
Additionally, Patheon <a href="https://business.cch.com/plsd/InreZantac6-16-25.pdf" target="_blank" rel="noreferrer noopener">contended</a> that no valid misrepresentation claim had been made. However, the court found that plaintiffs had adequately stated distinct claims for manufacturing and design defects.
The judge noted that plaintiffs alleged a flawed manufacturing process that caused ranitidine to form NDMA, a probable carcinogen, or that the manufacturing method contributed to the contamination. The court ruled that, at this stage of litigation, those allegations were sufficient to proceed.
On the negligence claim, the judge concluded that plaintiffs had met the specificity requirements under Rule 9(b), citing detailed allegations that Patheon exposed ranitidine to heat and humidity, leading to its degradation into NDMA.
The court emphasized that the claims were grounded in either violations of federal law or state law duties not solely governed by the FDA, meaning federal preemption did not apply at this stage.
Although the court, in June, agreed with Patheon that the plaintiffs had not asserted a misrepresentation claim, it allowed the remaining claims to proceed.
In May 2024, Pfizer settled 10,000 lawsuits alleging it concealed the cancer risks associated with its Zantac heartburn medication, marking the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38710835/pfizer-agrees-to-settle-over-10-000-lawsuits-about-cancer-risks-associated-with-discontinued-hear" rel="noreferrer noopener">largest resolution in the litigation</a>.&nbsp;
In October 2024, GSK reached agreements with ten plaintiff firms representing approximately 80,000 Zantac product liability&nbsp;cases in the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41295498/gsk-settles-majority-of-zantac-lawsuits-but-pipeline-doubts-remain" rel="noreferrer noopener">U.S. state courts</a>.
Price Action: PFE stock is down 0.43% at $25.67, and SNY stock is down 1.01% at $48.84 during the premarket session at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46363070/bitcoin-sets-all-time-high-at-118909-ethereum-xrp-surge-8-each" target="_blank" rel="noreferrer noopener">Bitcoin Sets All-Time High At $118,909, Ethereum, XRP Surge 8% Each</a></li>
</ul>
Image via Shutterstock

Biotech

Large Cap

News

Legal

General

Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony

While President Donald Trump's proposed 200% tariffs on pharmaceutical imports could potentially squeeze the profit margins, this stock is poised to &#8220;benefit&#8221; from the levies. 
What Happened: Trump announced on Tuesday that the pharma tariffs, part of a Section 232 investigation launched in April, are expected to be detailed by month's end, with a grace period of "about a year, year and a half" before implementation.
Barclays cautioned that a 200% tariff would "inflate production costs, compress profit margins, and risk supply chain disruptions.&#8221; However, the delay offers little relief, <a href="https://www.cnbc.com/2025/07/11/trump-200percent-pharma-tariffs-threaten-to-push-up-drug-prices-hit-margins.html">as</a> CNBC reported, quoting UBS analysts that it's "insufficient time" for firms to relocate manufacturing, typically a four-to-five-year process. 
But despite the potential negative impact on pharma companies, Louis Navellier told <a href="https://www.benzinga.com">Benzinga </a>that Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is &#8220;expected to benefit from tariffs on pharmaceutical imports, since the company has been boosting its domestic manufacturing.&#8221;
Additionally, Thomas Shipp, head of equity research at LPL Financial, told <a href="https://pro.benzinga.com/dashboard">Benzinga</a> that Lilly's attempt to try &#8220;to avoid PBMs,&#8221; exemplified by its direct-to-consumer model, &#8216;LillyDirect&#8217; in partnership with Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), positions it to bypass traditional pharmacy benefit managers, enhancing its resilience against tariff-related disruptions.
See Also: <a href="https://www.benzinga.com/markets/equities/25/07/46361386/bitcoin-breaches-118k-but-these-btc-mining-firms-are-still-priced-like-its-at-58k-heres-how-these-mining-stocks-could-explode">Bitcoin Breaches $118K, But These BTC Mining Firms Are Still Priced Like It&#8217;s At $58K: Here&#8217;s How These Mining Stocks Could Explode</a>
Why It Matters: Additionally, Lilly's strategic moves, including a $1.3 billion <a href="https://www.benzinga.com/m-a/25/06/45970361/eli-lilly-expands-into-gene-editing-with-verve-therapeutics-acquisition">acquisition of Verve Therapeutics</a>, signal its focus on innovation and U.S.-based growth. 
Ark Research noted that this acquisition validates gene-editing therapies for cardiovascular disease, a market with "trillions of dollars" in potential, as Lilly scales solutions like PCSK9-targeting therapies that reduce LDL-C by up to 69%.
Apart from the effects on the profitability of pharmaceutical companies, according to PhRMA, the tariffs could raise U.S. drug prices by $51 billion annually with just a 25% tariff levy, potentially increasing costs by 12.9%.
Price Action: Eli Lilly stock declined 0.078% in premarket on Friday; it was up 1.62% on a year-to-date basis but down by 15.36% over the last year.
Benzinga Edge Stock Rankings shows that LLY had a weak momentum and value ranking; however, its growth and quality metrics were very strong. The details of all the important indicators are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="163" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-1024x163.png" alt="" class="wp-image-981662" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-1024x163.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-300x48.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-768x122.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge.png 1039w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
These are some pharma stocks and ETFs that could be impacted as Trump warned on Tuesday that long-awaited industry-wide tariffs would be announced "very soon".
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma Stocks</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</td>
<td>1.62%</td>
<td>-15.36%</td>
</tr>
<tr>
<td>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</td>
<td>8.67%</td>
<td>14.77%</td>
</tr>
<tr>
<td>Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</td>
<td>-14.56%</td>
<td>19.07%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)</td>
<td>-21.73%</td>
<td>-48.18%</td>
</tr>
<tr>
<td>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</td>
<td>-3.12%</td>
<td>-10.05%</td>
</tr>
<tr>
<td>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</td>
<td>24.66%</td>
<td>63.70%</td>
</tr>
<tr>
<td>Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>-15.28%</td>
<td>-34.85%</td>
</tr>
<tr>
<td>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>15.85%</td>
<td>-7.60%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</td>
<td>9.49%</td>
<td>5.34%</td>
</tr>
</tbody>
</table>
</figure>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>3.50%</td>
<td>-3.73%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>3.15%</td>
<td>-0.88%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>0.68%</td>
<td>-0.49%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-0.16%</td>
<td>2.31%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>25.74%</td>
<td>30.34%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-1.00%</td>
<td>-4.29%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-14.12%</td>
<td>-14.74%</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46336115/as-trump-calls-for-3-percentage-point-rate-cut-too-late-jerome-powell-to-resign-june-fed-minutes-sh">As Trump Calls For 3-Percentage Point Rate Cut, &#8216;Too Late&#8217; Jerome Powell To Resign, June Fed Minutes Show &#8216;Uncertainty&#8217; Reigns Supreme</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shuttertsock

ABBV

FTXH

GILD

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies

<a href="https://www.bloomberg.com/news/articles/2025-07-10/delaware-court-sides-with-zantac-makers-in-cancer-claims-suits" title="https://www.bloomberg.com/news/articles/2025-07-10/delaware-court-sides-with-zantac-makers-in-cancer-claims-suits">https://www.bloomberg.com/news/articles/2025-07-10/delaware-court-sides-with-zantac-makers-in-cancer-claims-suits</a>

'Delaware Court Sides With Zantac Makers In Cancer Claims' - Bloomberg News

Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Astellas Pharma Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ALPMF#OTC">ALPMF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ALPMY#OTC">ALPMY</a>) on Thursday <a href="https://newsroom.astellas.us/2025-07-10-XTANDI-R-Plus-Leuprolide-Significantly-Improves-Survival-Outcomes-in-Men-with-Non-Metastatic-Hormone-Sensitive-Prostate-Cancer-with-High-Risk-Biochemical-Recurrence?_gl=1&#x2A;io3uax&#x2A;_gcl_au&#x2A;MTgxMjM4ODIyNy4xNzUwMDg5NzEzLjE2ODQwOTM5MDUuMTc1MDk3NjkxOC4xNzUwOTc2OTE5&#x2A;_ga&#x2A;MTMzODE1NTQwNC4xNzM0MzgyMDk4&#x2A;_ga_MBTGG7KX5Y&#x2A;czE3NTIxNzIzMjMkbzUxOSRnMSR0MTc1MjE3MjkyMSRqNTQkbDAkaDYzMTEyOTQ4MA..">released</a> topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating Xtandi (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer with biochemical recurrence (BCR) <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">at high risk for metastasis</a>.
For patients treated with Xtandi plus leuprolide versus placebo plus leuprolide, EMBARK met the key secondary endpoint with a statistically significant and clinically <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46338864/xtandi-plus-leuprolide-significantly-improves-survival-outcomes-in-men-with-non-metastatic-hormone" rel="noreferrer noopener">meaningful improvement in OS</a>.
There was a favorable trend in results towards improved OS for patients treated with Xtandi monotherapy versus placebo plus leuprolide; however, the difference did not reach statistical significance.
Also Read: <a href="https://www.benzinga.com/25/02/43737281/pfizers-talzennaxtandi-combo-improves-survival-outcomes-in-metastatic-castration-resistant-prostate-cancer" target="_blank" rel="noreferrer noopener">Pfizer&#8217;s Talzenna/Xtandi Combo Improves Survival Outcomes In Metastatic Castration-Resistant Prostate Cancer</a>
No new safety signals were observed in the analysis, and the safety results were consistent with Xtandi&#8217;s demonstrated safety profile.
In the EMBARK study, patients were randomized to one of three study arms: Xtandi plus leuprolide, placebo plus leuprolide or XTANDI monotherapy.
An initial analysis was previously reported in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nejm.org%2Fdoi%2F10.1056%2FNEJMoa2303974%3Furl_ver%3DZ39.88-2003%26rfr_id%3Dori%3Arid%3Acrossref.org%26rfr_dat%3Dcr_pub%2520%25200pubmed&amp;esheet=54287549&amp;newsitemid=20250710409204&amp;lan=en-US&amp;anchor=The+New+England+Journal+of+Medicine&amp;index=1&amp;md5=878c841b90a3bbee8da8c9e6a73ed146" target="_blank" rel="noreferrer noopener">The New England Journal of Medicine</a> in 2023, demonstrating that the study met its primary endpoint with a statistically significant and clinically meaningful improvement in MFS for patients treated with Xtandi plus leuprolide versus placebo plus leuprolide.
The most common adverse events (occurring in ≥10% of patients) in the combination group and the leuprolide-alone group were hot flashes and fatigue. The most common adverse events in the monotherapy group were gynecomastia, hot flashes, and fatigue.
Xtandi is approved in over 80 countries, including the U.S., the EU and Japan.
Detailed OS results from EMBARK will be presented at a future medical meeting.
In May, Astellas and Pfizer <a href="https://www.pfizer.com/news/press-release/press-release-detail/astellas-and-pfizers-xtanditm-enzalutamide-shows-long-term" target="_blank" rel="noreferrer noopener">announced</a> longer-term follow-up results from an open-label extension of the Phase 3 ARCHES study, reporting a five-year follow-up of overall survival (OS) benefits and a 30% reduction in the risk of death in men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with Xtandi plus androgen deprivation therapy (ADT) compared to placebo plus ADT.
In March, the U.S. Food and Drug Administration (FDA) on Friday approved Novartis AG's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Pluvicto for <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44544720/fda-oks-novartis-prostate-cancer-treatment-triples-eligible-patient-pool" rel="noreferrer noopener">prostate cancer patients</a>.
The expanded indication, which approximately triples the number of patients eligible to receive Pluvicto, is based on the Phase 3 PSMAfore trial results.
Novartis is investigating Pluvicto in earlier stages of the disease, including metastatic hormone-sensitive prostate cancer and oligometastatic prostate cancer.
PFE, ALPMY Price Actions: Pfizer stock is up 1.13% at $25.85; Astellas is down 0.64% at $9.40 at publication on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46347324/musk-says-grok-coming-to-teslas-by-next-week-evs-getting-the-smartest-ai-in-the-world" target="_blank" rel="noreferrer noopener">Musk Says Grok Coming To Teslas By Next Week: EVs Getting &#8216;The Smartest AI In The World&#8217;</a></li>
</ul>
Photo: Shutterstock

ALPMF

ALPMY

Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study

President Donald Trump is <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46269036/scott-bessent-says-tariff-rates-set-to-boomerang-back-in-august-for-countries-faili">sticking to his Aug. 1 deadline</a> to reimpose steep tariffs, but the stock market doesn&#8217;t seem too worried. On Reddit&#8217;s <a href="https://www.reddit.com/r/stocks/comments/1luos7o/so_why_is_the_stock_market_completely_ignoring/">r/stocks</a>, one confused investor posted, &#8220;Trump just announced plans to do <a href="https://www.benzinga.com/markets/25/05/45486508/scott-bessent-signals-liberation-day-2-0-coming-if-countries-dont-sign-trade-deals-president-trump-has-put-them-on-notice">Liberation Day 2.0</a> all over again, but this time the stock market stays&#8230; up??? Does Wall Street simply not care about the economy anymore?&#8221;
<h2 class="wp-block-heading">Markets Shrug Off Tariff Threats</h2>
Wall Street dipped slightly on Tuesday, with the <a href="https://finance.yahoo.com/news/live/stock-market-today-dow-sp-500-slip-as-trump-stays-firm-on-august-tariff-deadline-announces-copper-duties-200133528.html">Dow falling</a> about 0.4% and the S&amp;P 500 slipping just 0.07%. The Nasdaq barely edged higher. These modest moves followed Trump&#8217;s declaration on <a href="https://truthsocial.com/@realDonaldTrump/posts/114818149310161097">Truth Social</a> that there would be &#8220;no extensions granted&#8221; beyond the Aug. 1 deadline, adding that countries should expect to start paying new tariffs on that day. He also announced a <a href="https://www.benzinga.com/markets/equities/25/07/46305321/copper-price-surges-trump-tariffs-stocks-july-2025">50% tariff on copper imports</a> and threatened tariffs as high as 200% on pharmaceuticals.
Don't Miss:
<ul class="wp-block-list">
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
Despite the tough talk, many investors aren't reacting the <a href="https://www.benzinga.com/25/04/44710082/trumps-liberation-day-tariffs-wipe-out-174-billion-from-the-net-worth-of-worlds-top-10-billionaires-including-warren-buffett">way they did</a> when Trump tariffs were announced on April 2, a date he referred to as &#8220;Liberation Day&#8221;.
One Reddit user boiled it down like this: &#8220;Because no one is believing the boy who cried tariff.&#8221;
That skepticism is widespread. In the Reddit thread, a term kept popping up: TACO, short for &#8220;Trump Always Chickens Out.&#8221; It&#8217;s <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/06/46180782/trumps-tariff-clock-ticks-but-taco-traders-arent-losing-their-cool">Wall Street slang</a> that reflects a belief that Trump often makes bold announcements but backs down before serious consequences hit. &#8220;It took him like an hour yesterday to start saying that the new date isn&#8217;t 100%,&#8221; another commenter noted.
Others pointed out that the market has already priced in much of the tariff risk. &#8220;When he threatened with a +50% range, the market panicked. Now the tariffs are landing in the range that the market initially anticipated,&#8221; one top commenter explained, referencing the expected 10% to 25% tariff range.
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
Even Trump's newly announced copper tariff pushed futures up more than 10%, while pharmaceutical stocks like Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) pulled back after an early rally. Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) also <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46302633/amazon-stock-slips-as-early-prime-day-sales-data-disappoints">slipped</a> about 1% as its extended Prime Day began, with some investors watching for signs that tariffs are inflating consumer prices.
Still, some think the market is underestimating the damage. &#8220;We won't really know the impact until the fall,&#8221; one Reddit investor cautioned, suggesting that companies might temporarily absorb costs before passing them on.
In short, traders may have grown numb to Trump's tariff threats. &#8220;The market believes Trump isn&#8217;t serious and will back down before any real consequences emerge,&#8221; one commenter said. Another added: &#8220;Eventually he won&#8217;t chicken out,&#8221; hinting that investor complacency could backfire if Trump follows through this time.
For now, Wall Street appears more focused on Federal Reserve policy and the upcoming Q2 earnings season.&nbsp;
As one Redditor put it, &#8220;The stock market isn&#8217;t the economy.&#8221;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold">create customized gold IRAs to help shield their savings from inflation and economic turbulence. </a></li>
</ul>
Image: Shutterstock

An Investor Wonders Why Trump's Tariffs Aren't Shaking The Markets. 'Does Wall Street Simply Not Care About The Economy Anymore?'

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) supplemental Biologics License Application (sBLA) for Spikevax, the company&#8217;s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.
The company&#8217;s COVID-19 vaccine, mRNA-1273, was previously available for pediatric populations under Emergency Use Authorization.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46168811/modernas-mrna-flu-vaccine-outperforms-standard-shots" rel="noreferrer noopener">Moderna&#8217;s mRNA Flu Vaccine Outperforms Standard Shots</a>
&#8220;COVID-19 continues to pose a significant potential threat to children, especially those with underlying medical conditions. Vaccination can be an important tool for protecting our youngest against severe disease and hospitalization,&#8221; said Stéphane Bancel, CEO of Moderna. &#8220;We appreciate the FDA&#8217;s diligent scientific review and approval of Spikevax for pediatric populations at increased risk for COVID-19 disease.&#8221;
Moderna<a target="_blank" href="https://investors.modernatx.com/news/news-details/2025/Moderna-Receives-Full-U-S--FDA-Approval-for-COVID-19-Vaccine-Spikevax-in-Children-Aged-6-Months-Through-11-Years-at-Increased-Risk-for-COVID-19-Disease/default.aspx" rel="noreferrer noopener"> expects</a> to have its updated Spikevax vaccine available for eligible populations in the U.S. for the 2025-2026 respiratory virus season.
Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) have requested that London's Court of Appeal reverse a previous decision that found their COVID-19 vaccine to be in violation of a Moderna patent.
In July 2024, the High Court's ruling declared one of Moderna's mRNA technology patents invalid but upheld another, confirming that Pfizer and BioNTech's Comirnaty <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39602190/london-high-court-ruling-fuels-pfizer-and-moderna-legal-dispute-over-covid-19-vaccine-patents" rel="noreferrer noopener">vaccine had infringed on it</a>.
Reuters reported that Pfizer and Moderna are trying to challenge a ruling that upheld a patent, after Judge Richard Meade allowed them to appeal his decision.
They argue that Moderna&#8217;s mRNA technology was simply a clear next step based on earlier research, so the patent shouldn&#8217;t be valid. However, Moderna believes the judge made the right decision and that the ruling should remain in place.
An alliance of medical and public health organizations filed a lawsuit on Monday against Secretary of Health and Human Services Robert F. Kennedy Jr.
The plaintiffs contend that Kennedy has launched an "assault on science, public health, and evidence-based medicine" through unilateral and arbitrary changes to COVID-19 vaccine recommendations for children <a href="https://www.benzinga.com/news/health-care/25/07/46303191/medical-groups-sue-rfk-jr-for-assault-on-science-over-unlawful-covid-19-vaccine-rollbacks" target="_blank" rel="noreferrer noopener">and pregnant individuals</a>.
According to a recent media report, Dr. Vinay Prasad, the U.S. Food and Drug Administration's (FDA) top vaccine official, overruled agency scientists to limit the approval of two COVID-19 vaccines, despite internal recommendations to clear <a href="https://www.benzinga.com/news/health-care/25/07/46250723/rfk-jr-influence-evident-as-vaccine-chief-overrules-scientists-limits-covid-19-vaccine-approval" target="_blank" rel="noreferrer noopener">them for broader use</a>.
FDA scientists had recommended full approval for updated COVID vaccines from Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) and Moderna for individuals aged 12 and older, citing favorable risk-benefit analyses.
But Prasad restricted the shots to those at higher risk, seniors and people with underlying health conditions, arguing that declining hospitalization and death rates from COVID-19 shifted <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46250723/rfk-jr-influence-evident-as-vaccine-chief-overrules-scientists-limits-covid-19-vaccine-approval" rel="noreferrer noopener">the balance of risks and benefits</a>.
Price Action: MRNA stock is up 3.60% at $33.97 at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/biotech/25/07/46345543/klotho-stock-delivers-1222-biotech-blowout-opportunity-or-bubble" target="_blank" rel="noreferrer noopener">Klotho Stock Delivers 1,222% Biotech Blowout: Opportunity or Bubble?</a></li>
</ul>
Photo: Shutterstock

Movers

Trading Ideas

BNTX

MRNA

NVAX

FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months

<ul>
<li>XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical recurrence (BCR)</li>
</ul>
Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating XTANDI&#xAE; (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as nonmetastatic castration-sensitive prostate cancer or nmCSPC) with biochemical recurrence (BCR) at high risk for metastasis.
For patients treated with XTANDI plus leuprolide versus placebo plus leuprolide, EMBARK met the key secondary endpoint with a statistically significant and clinically meaningful improvement in OS. Results also showed a favorable trend towards improved OS for patients treated with XTANDI monotherapy versus placebo plus leuprolide, however the difference did not reach statistical significance. No new safety signals were observed in the analysis, and the safety results were consistent with the demonstrated safety profile of XTANDI.
XTANDI is currently approved in more than 80 countries, including in the United States, European Union, and Japan. Detailed OS results from EMBARK will be presented at a future medical meeting.
 &nbsp;

Pfizer And Astellas Pharma Report Topline Results From OS Analysis From Phase 3 EMBARK Study Evaluating XTANDI, In Combination With Leuprolide And As Monotherapy, In Men With nmHSPC With High Risk BCR

Market veteran Warren Buffett, famous for his value investing, is indirectly invested in high-dividend yield stocks via Berkshire Hathaway Inc.&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRA#NYSE">BRA</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) subsidiary New England Asset Management.
What Happened: In 1998, Berkshire Hathaway acquired General Re Corp., which in turn owned New England Asset Management (NEAM).
Therefore, NEAM is a wholly owned subsidiary of Berkshire Hathaway. While Buffett doesn&#8217;t directly oversee NEAM&#8217;s investment decisions, the portfolio managed by NEAM is considered part of Berkshire Hathaway&#8217;s overall holdings.
Thus, according to its 13F filings, NEAM holds at least nine stocks that have a dividend yield ranging from 5% to 10.5%.
While most of these nine stocks constitute less than 1% of NEAM&#8217;s 122 holdings as of the end of the first quarter of 2025, only Kraft Heinz Co. is common between Berkshire and NEAM&#8217;s portfolio.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Company</td>
<td>Value (as of March 31)</td>
<td>% Of Holdings (as of March 31)</td>
<td>Number Of Shares</td>
<td>Change From Dec. 31, 2024 (in %)</td>
</tr>
<tr>
<td>Kraft Heinz Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>)</td>
<td>$2.215 million</td>
<td>0.40%</td>
<td>72,810</td>
<td>1%</td>
</tr>
<tr>
<td>Golub Capital BDC Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBDC#NASDAQ">GBDC</a>)</td>
<td>$3.525 million</td>
<td>0.60%</td>
<td>232,876</td>
<td>0%</td>
</tr>
<tr>
<td>Ares Capital Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCC#NASDAQ">ARCC</a>)</td>
<td>$5.005 million</td>
<td>0.80%</td>
<td>225,900</td>
<td>0%</td>
</tr>
<tr>
<td>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</td>
<td>$3.939 million</td>
<td>0.60%</td>
<td>155,448</td>
<td>1%</td>
</tr>
<tr>
<td>Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</td>
<td>$2.407 million</td>
<td>0.40%</td>
<td>39,476</td>
<td>1%</td>
</tr>
<tr>
<td>Campbell&#8217;s Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>)</td>
<td>$2.582 million</td>
<td>0.40%</td>
<td>64,690</td>
<td>1%</td>
</tr>
<tr>
<td>Realty Income Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>)</td>
<td>$3.198 million</td>
<td>0.50%</td>
<td>55,140</td>
<td>NEW</td>
</tr>
<tr>
<td>Lamar Advertising Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAMR#NASDAQ">LAMR</a>)</td>
<td>$6.577 million</td>
<td>1.10%</td>
<td>57,805</td>
<td>1%</td>
</tr>
<tr>
<td>Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>)</td>
<td>$8.926 million</td>
<td>1.40%</td>
<td>196,795</td>
<td>9%</td>
</tr>
</tbody>
</table>
</figure>
Meanwhile, these stocks have not performed well on a year-to-date basis, but their high dividend yields are what make them lucrative, as per <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
These yields are considered high when compared to the SPDR S&amp;P 500 ETF Trust&#8217;s 1.2% dividend yield as of March 21, highlights <a href="https://www.benzinga.com/quote/SPY/dividends">Benzinga</a>.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Company</td>
<td>Dividend Yield</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>Kraft Heinz Co. </td>
<td>6.10%</td>
<td>-14.10%</td>
<td>-17.23%</td>
</tr>
<tr>
<td>Golub Capital BDC Inc. </td>
<td>10.50%</td>
<td>-2.75%</td>
<td>-5.29%</td>
</tr>
<tr>
<td>Ares Capital Corp. </td>
<td>8.60%</td>
<td>0.95%</td>
<td>6.46%</td>
</tr>
<tr>
<td>Pfizer Inc. </td>
<td>6.70%</td>
<td>-3.72%</td>
<td>-7.58%</td>
</tr>
<tr>
<td>Bristol-Myers Squibb Co. </td>
<td>5.30%</td>
<td>-17.17%</td>
<td>15.12%</td>
</tr>
<tr>
<td>Campbell&#8217;s Co. </td>
<td>5.00%</td>
<td>-26.15%</td>
<td>-31.60%</td>
</tr>
<tr>
<td>Realty Income Corp.</td>
<td>5.60%</td>
<td>9.30%</td>
<td>8.97%</td>
</tr>
<tr>
<td>Lamar Advertising Co. </td>
<td>5.00%</td>
<td>2.12%</td>
<td>4.26%</td>
</tr>
<tr>
<td>Verizon Communications Inc.</td>
<td>6.30%</td>
<td>7.09%</td>
<td>4.26%</td>
</tr>
</tbody>
</table>
</figure>
See Also: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46293440/tom-lee-loves-ethereum-but-is-solana-quietly-taking-over-this-expert-says-sol-will-outperform-eth-heres-more">Tom Lee Loves Ethereum, But Is Solana Quietly Taking Over? This Expert Says SOL Will &#8216;Outperform&#8217; ETH — Here&#8217;s More</a>
Why It Matters: Investors keenly follow the trades of the &#8216;Oracle of Omaha&#8217; &#8211; Buffett, for a deeper insight into his expertise.
His direct and indirect investments through Berkshire or other subsidiaries or holding companies influence the decisions of several investors.
Berkshire&#8217;s top holdings as of the first quarter 13F filings include Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), American Express Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>), Coca-Cola Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>), Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), and Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>).
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose slightly in premarket on Wednesday. The SPY was up 0.011% at $620.41, while the QQQ advanced 0.049% to $552.61, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46269226/stocks-just-hit-rare-golden-cross-for-1st-time-since-2023-heres-what-it-means-for-investors">Stocks Just Hit Rare Golden Cross For 1st Time Since 2023 — Here&#8217;s What It Means For Investors</a></li>
</ul>
Photo courtesy: mark reinstein / Shutterstock.com

Warren Buffett's Quiet Dividend Play: 9 High-Yield Stocks Held By A Berkshire Subsidiary

<ul>
<li>Real-world and implementation data describe effectiveness of long-acting Vocabria + Rekambys (cabotegravir + rilpivirine LA (CAB+RPV LA)) for HIV treatment and assess experiences of using Apretude (cabotegravir long-acting (CAB LA) for PrEP)in range of populations</li>
<li>New phase IIIb data look at preferences among treatment-naive adults offered the choice to switch to CAB+RPV LA after attaining rapid viral suppression with Dovato (DTG/3TC) daily oral therapy</li>
<li>Interim data from wave three of the Positive Perspectives study demonstrate impact of joint decision-making on HIV treatment satisfaction and health outcomes</li>
</ul>
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of abstracts from its innovative HIV treatment and prevention portfolio at the International AIDS Society 2025 Conference (IAS 2025) in Kigali, Rwanda. Key data will highlight the long-term effectiveness of Vocabria &amp; Rekambys, (branded as Cabenuva in the US, Canada and Australia) the company's complete long-acting injectable regimen for treatment; evaluate patient preference for long-acting injectables compared to daily oral therapy; and measure benefits of long-acting injectables in tackling common challenges associated with taking daily pills, including stigma and adherence.

ViiV Healthcare Showcases Data At IAS 2025 Highlighting Long-Term Effectiveness And Patient Preference For Long-Acting HIV Injectables Vocabria + Rekambys And Apretude Over Daily Oral Therapy

While multinational pharmaceutical firm Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) represents one of the top drugmakers in the world, that status alone hasn't exempted its equity from underperformance. In the past 52 weeks, LLY stock finds itself down almost 16%. Since the beginning of this year, LLY has barely poked its head above parity. Nevertheless, the statistical winds may point to an eventual recovery which options traders could potentially exploit.
Fundamentally, in the post-pandemic era, sentiment toward Eli Lilly skyrocketed thanks to its <a href="https://www.benzinga.com/news/25/01/42933134/fda-approves-weight-loss-drug-zepbound-for-sleep-apnea-will-insurance-cover-this-1000-per-month-medication">weight-loss drug</a>. In 2023, the U.S. Food and Drug Administration (FDA) approved the Zepbound (tirzepatide), the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. An injectable prescription medication that helps adults with other weight-related problems, Zepbound's clinical trials showed promising results.
Thanks to this early success, Eli Lilly and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) effectively formed a duopoly in the weight-loss market. While this reality contributed to a significant valuation surge, competition started to heat up last year. With major pharmaceuticals like Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Roche Holding Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announcing advancements in the <a href="https://www.benzinga.com/general/biotech/24/07/39849867/exclusive-weight-loss-duopoly-breaks-as-eli-lilly-novo-plummet-market-wont-be-dominated-by-just-2">development of obesity-fighting drugs</a>, LLY stock entered into a frustrating consolidation channel.
Still, with the pharmaceutical giant incurring an extended period of red ink in the market, JPMorgan analyst Chris Schott is essentially making the case that Eli Lilly is undervalued. Specifically, prescriptions for Zepbound and Mounjaro (an injectable <a href="https://www.lilly.com/news/media/media-kits/mounjaro">medicine</a> for adults with type 2 diabetes) are running ahead of expectations in the second quarter. As such, this performance may allow the pharmaceutical to beat and raise guidance throughout 2025.
Even with the <a href="https://www.benzinga.com/content/45261458/is-eli-lilly-a-buy-after-weak-earnings-and-cvs-novo-partnership">formulary change</a> by CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) putting around 200,000 patients at risk of losing access, Schott states that Eli Lilly's market share — which stands at about 70% to 75% of new patients — and strong momentum may help the company easily absorb the impact.
<h2 class="wp-block-heading">Statistical Backdrop Could Point To A Recovery In LLY Stock</h2>
Although the fundamental narrative of LLY stock is intriguing, it may also be a presuppositional leap. Essentially, the conclusion that LLY is undervalued is already embedded in the premise (that the market is not fully pricing in the good news for Eli Lilly).
If one thinks about it, it's an extraordinary claim. LLY stock routinely ranks among the most actively traded securities. That the market is somehow mispricing the pharmaceutical giant is an assertion that requires extraordinary evidence. In my opinion, if such evidence exists, it will likely materialize in the statistical realm as it's the arena that few (if any) analysts venture into.
A significant barrier to statistical analysis of the financial markets is the deployment of continuous scalar signals, such as share price or various valuation ratios. Because these signals are non-stationary, it's difficult (if not outright impossible) to extract meaningful insights based on the frequency of past analogs. Especially for highly traded securities like LLY stock, the measurement metrics constantly fluctuate.
To remedy this problem, we can impose stationarity by converting scalar signals into discrete states. For analyzing securities, converting share price into market breadth or sequences of accumulative and distributive sessions carries significant advantages. First, market breadth is essentially a representation of demand and demand is effectively binary. Second, clusters of binary codes can form distinct behavioral states, which can then serve as past analogs for extracting forward probabilities.
As an example, in the trailing two months, the price action of LLY stock can be interpreted as a "6-4-D" sequence: six up weeks, four down weeks, with a negative trajectory across the 10-week period. Admittedly, this process pancakes LLY's magnitude dynamism into a simple binary code. But the benefit is that this code can be easily segregated into distinct market profiles. From there, we can observe the likelihood of transition from one state to another.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-1024x576.jpg" alt="" class="wp-image-975331" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
With the above framework, we can identify that since January 2019, the 6-4-D sequence has materialized 38 times. From past analogs, we can also determine that in 68.42% of cases, the following week's price action results in upside, with a median return of 2.47%.
Accounting for the volatility on Monday, a realistic target over the next three weeks — assuming that the bulls gain and maintain control of the market — is just under the $800 level.
<h2 class="wp-block-heading">Playing The Odds With Eli Lilly</h2>
Based on the market intelligence above, bold speculators may consider the 785/790 bull call spread expiring Aug. 1. This transaction involves buying the $785 call and simultaneously selling the $790 call, for a net debit paid of $255 (the most that can be lost in the trade). Should LLY stock rise through the short strike price ($790) at expiration, the maximum reward is $245, a payout of 96%.
To be sure, the 780/790 bull spread expiring on the same day offers a payout of nearly 113%. However, the net debit required is $470, which puts significantly more capital at risk for only a modest increase in payout. Therefore, the 785/790 call spread is arguably more tempting.
Either way, both transactions require LLY stock to hit or exceed $790 on Aug. 1, which empirically appears to be a reasonable target. As a baseline, the chance that a long position in LLY will be profitable on any given week is quite high at 60.29%. However, the market's response to the 6-4-D sequence amplifies the odds in favor of the bullish speculator, thus incentivizing a debit-based strategy.
The opinions and views expressed in this content are those of the individual author and do not necessarily reflect the views of Benzinga. Benzinga is not responsible for the accuracy or reliability of any information provided herein. This content is for informational purposes only and should not be misconstrued as investment advice or a recommendation to buy or sell any security. Readers are asked not to rely on the opinions or information herein, and encouraged to do their own due diligence before making investing decisions.
Read More:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/options/25/07/46253955/khc-stock-bearish-pressure-statistical-reversal">Options Corner: Why Kraft Heinz Could Flip The Script On The Bears</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Options

Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround

<a href="https://www.gov.uk/drug-safety-update/abrysvov-pfizer-rsv-vaccine-and-arexvyv-gsk-rsv-vaccine-be-alert-to-a-small-risk-of-guillain-barre-syndrome-following-vaccination-in-older-adults" title="https://www.gov.uk/drug-safety-update/abrysvov-pfizer-rsv-vaccine-and-arexvyv-gsk-rsv-vaccine-be-alert-to-a-small-risk-of-guillain-barre-syndrome-following-vaccination-in-older-adults">https://www.gov.uk/drug-safety-update/abrysvov-pfizer-rsv-vaccine-and-arexvyv-gsk-rsv-vaccine-be-alert-to-a-small-risk-of-guillain-barre-syndrome-following-vaccination-in-older-adults</a>

UK's MHRA Says There Is Small Increase In Risk Of Guillain-Barré Syndrome Post Vaccination With Abrysvo And Arexvy In Adults Aged 60 Years & Older; Commission On Human Medicines Advise That Benefits Of Vaccination Against RSV Outweigh Small Risk Of Developing Guillain-Barré Syndrome; Currently No Evidence Of Increased Risk Of Guillain-Barré Syndrome In Pregnant Women Following Vaccination With Abrysvo

President Donald Trump&#8216;s $3.3 trillion domestic agenda bill, passed by House Republicans on Thursday, includes a significant but little-noticed victory for pharmaceutical companies that will cost taxpayers nearly $5 billion over the next decade.
What Happened: The legislation expands exemptions from Medicare&#8217;s drug price negotiation program, allowing manufacturers to keep prices higher for medications treating multiple rare diseases, The New York Times <a href="https://www.nytimes.com/2025/07/03/health/trump-bill-medicare-drug-prices.html">reported</a>. The Congressional Budget Office estimates this change will reduce government savings by $5 billion through 2034.
&#8220;This is essentially giving $5 billion back to the pharmaceutical industry,&#8221; said Benjamin Rome, a health policy researcher at Brigham and Women&#8217;s Hospital in Boston, according to the report. &#8220;It&#8217;s done in a way that is designed, on its face, to solve the problem of some misaligned incentives, but I don&#8217;t think it solves those problems.&#8221;
Under current law, costly drugs are exempt from Medicare price negotiations if they treat a single rare disease affecting fewer than 200,000 Americans. Drugmakers complained this policy discouraged them from seeking approval for additional rare disease treatments.
See Also: <a href="https://www.benzinga.com/news/politics/25/07/46257635/trump-administrations-ice-raids-compared-with-wwii-japanese-internment-camps-by-george-takei-politicians-lie-and-people-believe-that-lie">Trump Administration&#8217;s ICE Raids Compared With WWII Japanese Internment Camps By George Takei: &#8216;Politicians Lie, And People Believe That Lie&#8217;</a>
Why It Matters: This marks the most significant change to the Medicare negotiation program since Democrats created it in 2022, according to the report. 
The exemptions will apply to the third negotiation round affecting prices starting in 2028. Several drugs currently facing price cuts would have been spared under the new rules, including Imbruvica and Pomalyst for rare cancers.
The bill passed largely along party lines as part of Trump&#8217;s <a href="https://www.benzinga.com/news/politics/25/07/46255065/trumps-3-3-trillion-bill-passes-will-vulnerable-americans-pay-the-price">broader legislative package that includes tax cuts</a>, defense spending increases, and significant reductions to federal safety net programs. Democrats criticized the measure as favoring wealthy interests while burdening vulnerable Americans.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46258444/cognition-therapeutics-shares-jump-12-after-hours-following-encouraging-phase-2-alzheimers-trial-data">Cognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer&#8217;s Trial Data</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Maxim Elramsisy / Shutterstock.com

Politics

Trump's 'Big, Beautiful Bill' Hands $5 Billion Win To Big Pharma: Report

Dr. Vinay Prasad, the U.S. Food and Drug Administration&#8217;s (FDA) top vaccine official, overruled agency scientists to limit approval of two COVID-19 vaccines, despite internal recommendations to clear <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">them for broader use</a>.
The decision reflects a growing pattern of vaccine restrictions under the leadership of the U.S. Health and Human Services Secretary Robert F. Kennedy Jr.
FDA scientists had recommended full approval for updated COVID vaccines from Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) and Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) for individuals aged 12 and older, citing favorable risk-benefit analyses.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45887132/novavaxs-experimental-covid-19-influenza-combo-shot-shows-immune-response-among-older-adults-in-" rel="noreferrer noopener">Novavax&#8217;s Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial</a>
However, citing federal documents released Wednesday, ABC News reported <a target="_blank" href="https://abcnews.go.com/Health/wireStory/fda-vaccine-official-restricted-covid-vaccine-approvals-advice-123431749" rel="noreferrer noopener">that</a> Prasad restricted the shots to those at higher risk, seniors and people with underlying health conditions, arguing that declining hospitalization and death rates from COVID-19 shifted the balance of risks and benefits.
In a five-page memo, Prasad wrote that &#8220;even rare vaccination-related harms, both known and unknown, now have a higher chance of outweighing potential benefits,&#8221; highlighting the need for more cautious vaccine policy.
The vaccines were eventually approved in May, but under the narrower eligibility <a target="_blank" href="https://www.benzinga.com/government/regulations/25/05/45537919/fda-limits-annual-covid-19-boosters-to-high-risk-americans-demands-new-trials-for-healthy-adults-in-policy-shift-under-rfk-jr" rel="noreferrer noopener">criteria dictated by Prasad</a>.
Novavax&#8217;s shot, Nuvaxovid, is the only protein-based COVID vaccine available in the U.S., while Moderna&#8217;s mNexspike is a lower-dose, updated version of its <a target="_blank" href="https://www.benzinga.com/news/fda/25/06/45719840/modernas-new-covid-vaccine-secures-fda-clearance-for-seniors-at-risk-individuals" rel="noreferrer noopener">original mRNA-based vaccine</a>.
Prasad also cited the risk of myocarditis, a rare heart inflammation, especially in younger people, as a key reason for restricting Moderna&#8217;s shot.
He directed the company to conduct further studies as a condition for approval. The FDA also added updated warning labels for Moderna and Pfizer Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) vaccines regarding myocarditis, though external researchers say such cases are typically mild and resolve quickly.
Top FDA leaders rarely intervene in the product review, making Prasad&#8217;s decision notable. He was appointed in May after Dr. Peter Marks resigned over policy disagreements with Kennedy.
In May, Kennedy, in a&nbsp;video&nbsp;posted to the social media platform X, announced that the COVID-19 vaccine will no longer be among the recommended vaccines for pregnant women and healthy children on the U.S. Centers for Disease Control and <a target="_blank" href="https://www.benzinga.com/25/05/45624037/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-kids" rel="noreferrer noopener">Prevention&#8217;s immunization schedule</a>.
Price Action: At the last check on Thursday, Moderna (MRNA) stock saw an increase of 1.34%, trading at $30.69, while Novavax (NVAX) stock rose by 0.67% to $6.81. Pfizer (PFE) stock was also up at the last check.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/contracts/25/07/46249640/astrazeneca-in-15b-talks-for-drug-that-could-upend-lung-cancer-treatment" target="_blank" rel="noreferrer noopener">AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment</a></li>
</ul>
Photo via Shutterstock

Government

RFK Jr. Influence Evident As Vaccine Chief Overrules Scientists, Limits COVID-19 Vaccine Approval

On July 2, 2025, it was reported that Senator Ron L Wyden executed a sale of Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) stock, valued between $1,001 and $15,000. The transaction, recorded in the July filing, was made on June 3, 2025.
At the time of writing, Pfizer shares are trading up 0.33% at $25.4.
<h3>Senator's Recent Trading Activity</h3>
In the past three years, Ron L Wyden made 20 stock trades totaling more than $596 thousand. The largest trades involved stocks like PayPal Holdings and United Parcel Service. Their most notable trades made recently include key transactions: 
<ul>
<li>Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>): $1,001 - $15,000 Sale</li>
</ul>
Here's a summary of Ron L Wyden's recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer</td>
<td>PFE</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-06-03</td>
</tr>
</tbody>
</table>
If you want to stay updated on Ron L Wyden's trades and other congressional members, check out our <a href="https://www.benzinga.com/gov-trades/members/ron-l-wyden">government trades tool</a> to track their activity in real time!
<h3>Why Congressional Transactions Matter</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>Why Congressional Transactions Matter</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recent Report Shows That Sen. Ron L Wyden Sold Up to $15K Worth of Pfizer Stock

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 6.79%</li>
<li>Guggenheim analyst Vamil Divan reiterated a Buy rating on March 18, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Citigroup analyst Andrew Baum maintained a Neutral rating and cut the price target from $30 to $29 on Jan. 28, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On June 26, Pfizer announced positive topline Phase 3 results for HYMPAVZI&#x2122; in Hemophilia A or B with inhibitors.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703">latest PFE news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703"><img loading="lazy" decoding="async" width="917" height="822" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03065950/image-39.png" alt="" class="wp-image-971905" style="width:653px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03065950/image-39.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03065950/image-39-300x269.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03065950/image-39-768x688.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 3.99%</li>
<li>Truist Securities analyst David Macdonald maintained a Buy rating and raised the price target from $82 to $84 on May 12, 2025. This analyst has an accuracy rate of 67%.</li>
<li>RBC Capital analyst Ben Hendrix maintained an Outperform rating and boosted the price target from $74 to $81 on May 5, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: CVS Health will hold a conference call on Thursday, July 31 to discuss second quarter 2025 financial results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703">CVS news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703"><img loading="lazy" decoding="async" width="912" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070012/image-40.png" alt="" class="wp-image-971907" style="width:571px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070012/image-40.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070012/image-40-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070012/image-40-768x696.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<h3 class="wp-block-heading">Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 3.93%</li>
<li>Citigroup analyst Andrew Baum downgraded the stock from Buy to Neutral and cut the price target from $115 to $84 on May 14, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Guggenheim analyst Vamil Divan reiterated a Buy rating with a price target of $115 on April 17, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Recent News: On July 2, the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for Merck's new supplemental Biologics License Application (sBLA) seeking approval to update the U.S. product label based on the Phase 3 ZENITH trial for Winrevair (sotatercept-csrk).</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest MRK <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703"><img loading="lazy" decoding="async" width="911" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070051/image-41.png" alt="" class="wp-image-971910" style="width:570px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070051/image-41.png 911w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070051/image-41-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070051/image-41-768x697.png 768w" sizes="(max-width: 911px) 100vw, 911px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46218519/jim-cramer-gives-utilities-stock-a-week-says-doge-not-done-clobbering-booz-allen"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46218519/jim-cramer-gives-utilities-stock-a-week-says-doge-not-done-clobbering-booz-allen">Jim Cramer Gives Utilities Stock &#8216;A Week,&#8217; Says DOGE &#8216;Not Done Clobbering&#8217; Booz Allen</a> </li>
</ul>
Photo via Shutterstock

Dividends

Price Target

Pre-Market Outlook

Analyst Ratings

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

<a href="https://www.nytimes.com/2025/07/02/health/fda-covid-vaccines.html" title="https://www.nytimes.com/2025/07/02/health/fda-covid-vaccines.html">https://www.nytimes.com/2025/07/02/health/fda-covid-vaccines.html</a>

'Top F.D.A. Official Overrode Scientists on Covid Shots; Records show that a top U.S. regulator rejected the recommendations of agency experts and limited the use of Covid vaccines.' - NY Times

The House Judiciary Committee has subpoenaed Dr. Philip Dormitzer, a former Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) executive, in connection with an investigation into claims that the company intentionally delayed the release of <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">clinical testing results</a> for its COVID-19 vaccine until after the 2020 presidential election.
The move signals an escalation in the panel's probe into whether political considerations influenced Pfizer's vaccine announcement timeline.
Dormitzer, who later joined British drugmaker GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), is considered a key witness in the inquiry.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46123159/pfizer-seeks-label-expansion-for-hemophilia-drug-after-promising-data" rel="noreferrer noopener">Pfizer Seeks Label Expansion For Hemophilia Drug After Promising Data</a>
Benzinga reached out to Pfizer for comment.
According to the committee, he has not voluntarily complied with previous requests to appear or provide documents.
The subpoena, first reported by CNN, reflects lawmakers&#8217; belief that Dormitzer&#8217;s testimony is central to understanding internal decision-making at Pfizer during the development of the vaccine.
The committee points to allegations that Dormitzer, after joining GSK, told colleagues that Pfizer had deliberately delayed disclosing the vaccine&#8217;s effectiveness until after Election Day.
The CNN <a target="_blank" href="https://edition.cnn.com/2025/06/30/politics/pfizer-covid-vaccine-philip-dormitzer" rel="noreferrer noopener">report </a>added that the Wall Street Journal previously reported that GSK had flagged those statements to federal prosecutors in New York.
According to House Judiciary Chair Jim Jordan, GSK provided information from a human resources meeting in November 2024 in which Dormitzer allegedly expressed concern about being investigated by a future Trump administration, suggesting the vaccine announcement timing was "not a coincidence."
Further, Jordan's letter cites claims that Dormitzer informed colleagues that Pfizer&#8217;s top R&amp;D leadership intentionally slowed clinical testing so that it would not conclude before the election results were known. The Judiciary Committee has received some records from GSK but has not made them public.
Pfizer announced the COVID-19 vaccine's effectiveness on Nov. 9, 2020, six days after Election Day.
CEO Albert Bourla has previously denied political motives, telling CNN that the timing was based solely on data readiness and regulatory review, not election considerations.
While the committee has not issued a subpoena to Pfizer, it seeks information directly from the company as the investigation progresses.
Price Action: PFE stock is currently 0.80% higher at $25.24, as of the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46226585/microsoft-cuts-9000-jobs-in-second-2025-layoff" target="_blank" rel="noreferrer noopener">Microsoft Cuts 9,000 Jobs In Second 2025 Layoff As AI Expansion Pushes Cost Controls</a></li>
</ul>
Photo: Shutterstock

Lawmakers Investigate Whether Pfizer Delayed COVID-19 Vaccine Results For Political Reasons

<a href="https://www.bloomberg.com/news/articles/2025-07-01/rfk-jr-vows-overhaul-of-lawsuit-sparing-vaccine-injury-program?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-07-01/rfk-jr-vows-overhaul-of-lawsuit-sparing-vaccine-injury-program?embedded-checkout=true</a>

'RFK Jr. Vows Overhaul of Lawsuit-Sparing Vaccine Injury Program'- Bloomberg

Personal finance expert Suze Orman says she&#8217;s confident the stock market is headed higher, despite some alarming signs in the broader economy. In her recent <a href="https://www.youtube.com/watch?v=eoC3d8kt6e4">video</a>, she acknowledged that things feel unstable right now, but urged her audience to stay calm and take a long-term view.
<h2 class="wp-block-heading">Unusual Economic Signals</h2>
&#8220;There is something going on in this economy that I really don&#8217;t like,&#8221; Orman said, citing how traditional patterns are breaking. Typically, when markets drop, investors move into bonds, causing bond prices to rise and interest rates to fall. But that hasn&#8217;t been happening. &#8220;Interest rates in <a href="https://www.benzinga.com/25/05/45654448/bond-market-caught-between-rate-cut-hopes-and-fed-cautionwhat-investors-can-do-now">bonds</a> went up and up and up,&#8221; she said. &#8220;That isn&#8217;t what you want to see in normal markets.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li>Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">invest with $1,000 at just $0.30/share.</a></li>
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
</ul>
Another red flag: the U.S. dollar. Orman explained that during times of global uncertainty, foreign money usually flows into the dollar, strengthening it. But instead, &#8220;<a href="https://www.benzinga.com/markets/economic-data/25/06/45974992/everyone-now-hates-the-dollar-is-that-the-ultimate-buy-signal">the dollar has been getting weaker</a> and weaker and weaker.&#8221;
She suggested this could mean foreign investors are losing confidence in the U.S. &#8220;Maybe it&#8217;s that foreign countries don&#8217;t quite have the faith in us anymore that they used to. We haven&#8217;t exactly <a href="https://www.benzinga.com/25/03/44131125/tariff-update">been nice to them</a>.&#8221;
<h2 class="wp-block-heading">Shifting Her Own Strategy</h2>
With her own treasuries maturing, Orman said she is now choosing dividend-paying stocks instead of rolling her money back into treasuries. &#8220;Many <a href="https://www.benzinga.com/money/best-dividend-paying-stocks">dividend-paying stocks</a> right now are paying more in a dividend than the Treasury is paying in interest rates,&#8221; she said.
Trending: GoSun's Breakthrough Rooftop EV Charger Already Has 2,000+ Units Reserved — <a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor">Become an Investor in This $41.3M Clean Energy Brand Today</a>
She emphasized the importance of dollar-cost averaging: investing smaller amounts over time. This way, if stock prices fall, investors can buy more shares. &#8220;Even if it goes down because the markets go down&#8230; [your] income is fixed in the dividend, [so] your interest rate also goes up in there,&#8221; she explained.
One example she gave was Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), which has been trading around $24 a share with a <a href="https://www.benzinga.com/content/45601072/pfizers-7-5-dividend-income-haven-or-house-of-cards">dividend yield of about 7%</a>. &#8220;Now, is it possible that maybe they could cut the dividend? They&#8217;re not going to get rid of the dividend, as far as I&#8217;m concerned.&#8221;
<h2 class="wp-block-heading">Staying Invested In The Future</h2>
Orman advised investors to focus on sectors that reflect the future, particularly artificial intelligence and technology. She specifically recommended ETFs like VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>) and Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>). &#8220;I want you to be investing in the future, not in the past anymore,&#8221; she said. &#8220;Artificial intelligence has absolutely changed the face of money and the face of the future.&#8221;
See Also: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a>
Despite today's economic uncertainty, Orman remains optimistic. &#8220;Believe it or not, I have total belief that these markets are going to continue up without a shadow of a doubt,&#8221; she said. Even if she turns out to be only half right, she advised investors to act accordingly: invest 50% now and the rest later if prices fall.
&#8220;I&#8217;m still a total believer in the stock market. I think it is very, very possible you could see the [<a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45932660/exclusive-sp-500-new-all-time-highs-again-2025">S&amp;P 500</a>] skyrocket. I am a total believer in dividend-paying stocks,&#8221; she said. And if you don't need the income now, she added, &#8220;it is essential that you are reinvesting those dividends.&#8221;
Read Next: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
Image: Shutterstock

Suze Orman Believes The Stock Market Will Continue Climbing 'Without A Shadow Of A Doubt'

Pfizer Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) released topline results from the Phase 3 BASIS study evaluating Hympavzi (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors.
Phase 3 BASIS study in patients without inhibitors supported the FDA approval of <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41310468/fda-approves-pfizers-second-hemophilia-drug-with-six-months" rel="noreferrer noopener">Hympavzi in October 2024</a>.
The study met the primary endpoint and key secondary bleeding endpoints, demonstrating the superiority of once-weekly subcutaneous Hympavzi in improving key bleeding outcomes compared to on-demand treatment in a patient population where less burdensome treatment <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46111475/pfizer-announces-positive-topline-phase-3-results-for-hympavzi-in-hemophilia-a-or-b-with-inhibitor" rel="noreferrer noopener">approaches are needed</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44560065/fda-approves-sanofis-hemophilia-drug" rel="noreferrer noopener">FDA Approves Sanofi&#8217;s Hemophilia Drug</a>
The BASIS trial demonstrated that prophylactic treatment with Hympavzi resulted in a statistically significant and clinically relevant reduction in annualized bleeding rate (ABR) of treated bleeds in people with severe hemophilia A or B with inhibitors.
Forty-eight people living with hemophilia were treated with Hympavzi during 12 months versus an on-demand intravenous regimen with bypassing agents, administered as part of usual care in the six-month lead-in period.
Hympavzi was superior to on-demand treatment with a 93% reduction in ABR over 12 months (ABR 1.39 vs ABR on-demand 19.78; p &lt; 0.0001).
The superiority of Hympavzi was also demonstrated across all bleeding-related secondary endpoints, spontaneous bleeds, joint bleeds, target joint bleeds, and total bleeds, Pfizer announced on Thursday.
Hympavzi was generally well-tolerated, consistent with the non-inhibitor cohort of the BASIS study and Phase 1/2 results. No deaths or thromboembolic events were reported.
Analyses of the full Phase 3 dataset from the inhibitor cohort of the BASIS study are ongoing, and additional data will be presented at upcoming medical meetings.
Hympavzi&#8217;s mechanism of action is differentiated from those of FVIII and FIX replacement treatments. Instead of replacing missing or insufficient clotting factors, Hympavzi is intentionally designed to target tissue factor pathway inhibitor (TFPI), one of the body&#8217;s natural mechanisms that inhibits the initiation of blood clotting.
By targeting the Kunitz 2 domain of TFPI, Hympavzi may help re-establish balance between bleeding and blood clot formation. Its goal is to offer a combination of bleed protection, good tolerability, and straightforward administration.
Pfizer plans to discuss these data with regulatory authorities to initiate regulatory filings for Hympavzi for hemophilia patients with inhibitors.
Price Action: PFE stock is trading lower by 0.05% to $24.25 at last check Thursday
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/46109624/rfk-jr-overhauls-cdc-vaccine-panel-sparking-expert-backlash-boycott-from-top-medical-group" target="_blank" rel="noreferrer noopener">RFK Jr. Overhauls CDC Vaccine Panel, Sparking Expert Backlash, Boycott From Top Medical Group</a></li>
</ul>
Photo by ShU studio via Shutterstock

Pfizer Seeks Label Expansion For Hemophilia Drug After Promising Data

Press Releases

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

AM Best Affirms Credit Ratings of Blue Whale Re Ltd.

Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences

Management

INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)

Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030

Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts

Pfizer Declares Third-Quarter 2025 Dividend

Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors

ViiV Healthcare presents new data demonstrating positive real-world impact of its innovative long-acting injectables for HIV at IAS 2025

XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

ARVN

COLL

NTRB

NTRBW

ONCY

TEVA

TSX:ONC

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Comments

Pfizer

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL